AEGIRBIO specialised in biologic therapy therapeutic drug monitoring in the areas of autoimmune, cancer, and neurology. The concentrations of biologic drugs differ greatly between patients, resulting in needless side effects and poor therapeutic results. These high-cost medicines can be customised to enhance treatment results and save money for healthcare systems by measuring medication levels in individual patients. By pioneering Point of Care and Point of Need testing that may deliver findings in minutes, Aegirbio is creating new norms in this sector.
COVID-19 (SARS-COV-2) SALIVA TEST
The Aegirbio Viraspec COVID-19 Saliva Test is a simple lateral flow test that identifies COVID-19 in saliva samples quickly. A nasal swab or blood extraction is inconvenient when testing on youngsters or when repeated use is required.
The Viraspec COVID-19 Test employs a saliva and dilution liquid mixture that responds to the COVID-19 antigen in within 10 minutes, yielding a simple-to-read result. Human clinical studies have demonstrated that the test has a sensitivity of 90% for SARS-CoV-2 infections and a specificity of 99.9% when compared to RT-PCR.
Each Kit Includes:
- 25 Individually Pouched Test Cassettes
- 25 Collection Tubes
- 25 Extraction Buffer Tubes
- 25 Saliva Collectors
- 1 Workstation
- 1 Package Insert
NowMed have created long-lasting and long-term relationships by representing high-quality items in many fields of business for over 30 years. NowMed Sweden can now provide and guarantee a variety of services based on these experiences and responsible communication.
NowMed is energised by the prospect of aiding in the fight against the Corona virus and other known and undiscovered infectious diseases.
The Swedish diagnostic firm Aegirbio AB, which created the saliva-based fast test ViraspecTM, has chosen NowMed Sweden AB as its official Scandinavian sales and distribution partner.
Visit aegirbio.com for additional details.